{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:19:55Z","timestamp":1792545595956,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66092-1","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:02:07Z","timestamp":1764324127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5029-1519","authenticated-orcid":false,"given":"Songul","family":"Kucukcelebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek R.","family":"van \u2018t Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-0354","authenticated-orcid":false,"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry A. L. M.","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein Y. V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Onrust-van Schoonhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2653-7849","authenticated-orcid":false,"given":"Nina E. M.","family":"Rozendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Fellah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Vadgama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Moskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3452-6771","authenticated-orcid":false,"given":"Koen","family":"Bezemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-840X","authenticated-orcid":false,"given":"Michail","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-6725","authenticated-orcid":false,"given":"Casper W. F.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-5607","authenticated-orcid":false,"given":"Ralph","family":"Stadhouders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1766","authenticated-orcid":false,"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0192-5354","authenticated-orcid":false,"given":"Aniek E.","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Enninga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet V.","family":"Ambarkhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-2951","authenticated-orcid":false,"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-1517","authenticated-orcid":false,"given":"Christianne","family":"Groeneveldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-2157","authenticated-orcid":false,"given":"Casper H. J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"66092_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"66092_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"66092_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74, 2913\u20132921 (2014).","journal-title":"Cancer Res"},{"key":"66092_CR4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008\u20132020 (2020).","journal-title":"Lancet"},{"key":"66092_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker, M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 17, 801\u2013810 (2016).","journal-title":"Lancet Oncol."},{"key":"66092_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djad020","volume":"115","author":"M Luyendijk","year":"2023","unstructured":"Luyendijk, M. et al. Changes in survival in de novo metastatic cancer in an era of new medicines. J. Natl Cancer Inst. 115, 628\u2013635 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"66092_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/1073274821997430","volume":"28","author":"K Chen","year":"2021","unstructured":"Chen, K., Wang, X., Yang, L. & Chen, Z. The Anti-PD-1\/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. Cancer Control 28, 1073274821997430 (2021).","journal-title":"Cancer Control"},{"key":"66092_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"66092_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137 (2022).","journal-title":"J. Clin. Oncol."},{"key":"66092_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR16","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma, P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 17, 1590\u20131598 (2016).","journal-title":"Lancet Oncol."},{"key":"66092_CR17","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","volume":"25","author":"DT Le","year":"2019","unstructured":"Le, D. T. et al. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin. Cancer Res 25, 5493\u20135502 (2019).","journal-title":"Clin. Cancer Res"},{"key":"66092_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E. et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"66092_CR19","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66092_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ags3.12225","volume":"3","author":"T Murakami","year":"2019","unstructured":"Murakami, T. et al. Role of the tumor microenvironment in pancreatic cancer. Ann. Gastroenterol. Surg. 3, 130\u2013137 (2019).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"66092_CR22","unstructured":"Rojas L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 1-7 (2023)."},{"key":"66092_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med 30, 531\u2013542 (2024).","journal-title":"Nat. Med"},{"key":"66092_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"66092_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1067\/msy.2002.119937","volume":"131","author":"RM Dallal","year":"2002","unstructured":"Dallal, R. M. et al. Paucity of dendritic cells in pancreatic cancer. Surgery 131, 135\u2013138 (2002).","journal-title":"Surgery"},{"key":"66092_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 37, 289\u2013307 e9 (2020).","journal-title":"Cancer Cell."},{"key":"66092_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","volume":"169","author":"SP Lau","year":"2022","unstructured":"Lau, S. P. et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T cell responses in patients with pancreatic cancer: A phase I study. Eur. J. Cancer 169, 20\u201331 (2022).","journal-title":"Eur. J. Cancer"},{"key":"66092_CR28","unstructured":"van \u2018t Land F. R. et al. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. J Clin Oncol. JCO2302585 (2024)."},{"key":"66092_CR29","doi-asserted-by":"crossref","unstructured":"Lau S. P. et al. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer. 8 (2020).","DOI":"10.1136\/jitc-2020-000772"},{"key":"66092_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide, R. H. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu Rev. Med 71, 47\u201358 (2020).","journal-title":"Annu Rev. Med"},{"key":"66092_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612\u20131616 (2011).","journal-title":"Science"},{"key":"66092_CR32","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne, K. T. et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin. Cancer Res 27, 4574\u20134586 (2021).","journal-title":"Clin. Cancer Res"},{"key":"66092_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","volume":"41","author":"V Moreno","year":"2023","unstructured":"Moreno, V. et al. A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Invest N. Drugs 41, 93\u2013104 (2023).","journal-title":"Invest N. Drugs"},{"key":"66092_CR34","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","volume":"24","author":"J Aerts","year":"2018","unstructured":"Aerts, J. et al. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin. Cancer Res 24, 766\u2013776 (2018).","journal-title":"Clin. Cancer Res"},{"key":"66092_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"66092_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"66092_CR37","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2019.37.15_suppl.2527","volume":"37","author":"C Emiliano","year":"2019","unstructured":"Emiliano, C. et al. A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors. J. Clin. Oncol. 37, 2527 (2019).","journal-title":"J. Clin. Oncol."},{"key":"66092_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32141","volume":"145","author":"SMM Irenaeus","year":"2019","unstructured":"Irenaeus, S. M. M. et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J. Cancer 145, 1189\u20131199 (2019).","journal-title":"Int J. Cancer"},{"key":"66092_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(24)00191-8","volume":"25","author":"JG Aerts","year":"2024","unstructured":"Aerts, J. G. et al. Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2\/3 study. Lancet Oncol. 25, 865\u2013878 (2024).","journal-title":"Lancet Oncol."},{"key":"66092_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","volume":"6","author":"KB Long","year":"2016","unstructured":"Long, K. B. et al. IFN\u03b3 and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 6, 400\u2013413 (2016).","journal-title":"Cancer Discov."},{"key":"66092_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110 (2023).","journal-title":"Nat. Commun."},{"key":"66092_CR42","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","volume":"25","author":"JL Van Laethem","year":"2024","unstructured":"Van Laethem, J. L. et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol. 25, 853\u2013864 (2024).","journal-title":"Lancet Oncol."},{"key":"66092_CR43","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med 28, 1167\u20131177 (2022).","journal-title":"Nat. Med"},{"key":"66092_CR44","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med"},{"key":"66092_CR45","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/ijc.34293","volume":"152","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk, M. et al. Combination of PD-1\/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma. Int J. Cancer 152, 1438\u20131443 (2023).","journal-title":"Int J. Cancer"},{"key":"66092_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji, Y., Liu, P., Li, Y. & Bekele, B. N. A modified toxicity probability interval method for dose-finding trials. Clin. Trials 7, 653\u2013663 (2010).","journal-title":"Clin. Trials"},{"key":"66092_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"66092_CR48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","volume":"32","author":"D Risso","year":"2014","unstructured":"Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 32, 896\u2013902 (2014).","journal-title":"Nat. Biotechnol."},{"key":"66092_CR49","doi-asserted-by":"crossref","unstructured":"Bhattacharya A. et al. An approach for normalization and quality control for NanoString RNA expression data. Brief Bioinform. 22 (2021).","DOI":"10.1093\/bib\/bbaa163"},{"key":"66092_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"66092_CR51","unstructured":"Morpheus. https:\/\/software.broadinstitute.org\/morpheus."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66092-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66092-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66092-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:02:18Z","timestamp":1764324138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66092-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66092"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66092-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: SHvdB is a paid member of the study advisory board of Alligator Bioscience AB. KB reports personal fees from Amphera BV. RM and IE received consulting fees from Amphera BV and are stock owners of Amphera BV. PE and SVA are employed by Alligator Bioscience AB and hold stock options in Alligator Bioscience AB. JGJVA reports grants, personal fees, research support, and stock ownership from Amphera BV and personal fees from Bristol-Myers Squibb, Eli-Lilly, MSD, CureVac, Danone, Astra-Zeneca, and Novocure. JGJVA holds a patent for a tumor cell lysate (US20180296654A1), a patent for combination immunotherapy (US20220016164A1), and a patent for a biomarker for immunotherapy (11802315). CHJvE receives a consultancy fee from AIM ImmunoTech. All other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10609"}}